WUGEN Inc.

FLT201, Freeline Therapeutics ’ one-time gene therapy candidate for Gaucher disease, is among the latest three investigational products that have secured a place on PRIME, the European Medicines Agen

The UK may be Europe’s pre-eminent biotech sector but its potential has been held back by a huge shortfall in cash compared with the US. That could be about to change, with the launch this week of a l

Wugen Inc. has raised nearly $200m to date to fund its natural killer (NK) cell and chimeric antigen receptor T-cell (CAR-T) therapies, including a $172m series B venture capital round announced on 1

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Picks Up Perception’s R-Ketamine